FindTrial
Sign In

AFM24

DRUG3 trials

Sponsors

Affimed GmbH, Affimed GmbH, NKGen Biotech, Inc., Affimed GmbH

Conditions

Advanced Solid TumorAdvanced/Metastatic EGFR-expressing CancersCarcinoma, Non-Small-Cell LungColorectal NeoplasmsMetastatic TumorRefractory TumorSquamous Cell Carcinoma of Head and Neck

Phase 1

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
TerminatedNCT05099549
NKGen Biotech, Inc.Advanced Solid Tumor, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms +3
Start: 2021-11-03End: 2023-09-21Updated: 2024-03-01
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
TerminatedNCT05109442
Affimed GmbHAdvanced Solid Tumor
Start: 2021-11-19End: 2025-06-11Updated: 2025-08-20
A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
CompletedCTIS2024-511999-32-00
Affimed GmbH, Affimed GmbHAdvanced/Metastatic EGFR-expressing Cancers
Start: 2021-11-19End: 2025-06-11Target: 127Updated: 2025-03-06

Related Papers

Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic <i>EGFR</i> -expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.
Journal of Clinical Oncology2025-05-282 citations
Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with <i>EGFR</i> kinase domain mutations ( <i>EGFR</i> mut): Initial results from a phase 2a study.
Journal of Clinical Oncology2025-05-28
Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2024-06-0111 citations
AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose-escalation study.
JCO Global Oncology2023-08-013 citations
746 AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR<sup>+</sup>) solid tumors: Initial results from the phase 1 dose-escalation study
Regular and Young Investigator Award Abstracts2022-11-01
AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid tumors: Phase 1/2a study design and rationale.
Journal of Clinical Oncology2022-06-015 citations
The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-012 citations